AVBP
ArriVent BioPharma, Inc. Common Stock NASDAQ Listed Jan 26, 2024$32.70
After hrs
$32.70
+0.00%
Mkt Cap $1.5B
52w Low $16.10
92.4% of range
52w High $34.06
50d MA $29.40
200d MA $23.39
P/E (TTM)
—
EV/EBITDA
—
P/B
4.1x
Debt/Equity
0.0x
ROE
-54.1%
P/FCF
-7.6x
RSI (14)
57.40
ATR (14)
$1.74
Beta
0.86
50d MA
$29.40
200d MA
$23.39
Avg Volume
517.2K
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
18 Campus Boulevard · Newtown Square, PA 19073 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | AMC | -0.87 | -0.78 | +10.3% | 25.25 | +0.6% | -7.2% | +5.9% | +2.1% | -2.8% | -2.1% | — |
| Nov 10, 2025 | AMC | -0.78 | -0.83 | -6.4% | 18.60 | -0.5% | +4.2% | +4.2% | -2.6% | +5.1% | +0.0% | — |
| Aug 11, 2025 | AMC | -0.70 | -0.90 | -28.6% | 17.39 | +1.0% | -2.5% | +6.3% | +3.3% | +4.9% | -1.5% | — |
| May 12, 2025 | AMC | -0.66 | -1.90 | -187.9% | 19.99 | -0.5% | -4.5% | -1.8% | +2.6% | +0.6% | -0.1% | — |
| Mar 3, 2025 | AMC | -0.78 | -0.60 | +23.1% | 22.03 | -1.6% | -0.3% | +2.3% | -2.9% | +0.3% | -0.6% | — |
| Nov 14, 2024 | AMC | -0.82 | -0.61 | +25.6% | 28.08 | +1.4% | -3.1% | -0.6% | +1.4% | -0.0% | -3.0% | — |
| Aug 14, 2024 | AMC | -0.65 | -0.65 | +0.0% | 23.95 | +0.5% | -0.4% | +2.1% | -1.5% | +0.9% | -1.2% | — |
| May 8, 2024 | AMC | -0.84 | -0.70 | +16.7% | 17.36 | +0.0% | +3.6% | -1.6% | +1.3% | +3.0% | +5.6% | — |
| Jan 26, 2024 | AMC | -1.10 | -0.70 | +36.4% | 20.00 | +0.0% | -0.5% | +10.5% | -2.0% | +2.0% | -0.6% | — |
| Sep 30, 2023 | AMC | — | -0.43 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | — | -0.64 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | AMC | — | -0.36 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 24 | Citigroup | Maintains | Buy → Buy | — | $31.00 | $31.33 | +1.1% | -1.9% | -0.3% | -1.0% | +0.0% | +3.5% |
| Mar 23 | B. Riley Securities | Maintains | Buy → Buy | — | $22.02 | $22.34 | +1.5% | +0.7% | -1.0% | +3.6% | -4.1% | -1.7% |
| Mar 6 | Citigroup | Maintains | Buy → Buy | — | $25.25 | $25.41 | +0.6% | -7.2% | +5.9% | +2.1% | -2.8% | -2.1% |
| Mar 6 | Oppenheimer | Maintains | Outperform → Outperform | — | $25.25 | $25.41 | +0.6% | -7.2% | +5.9% | +2.1% | -2.8% | -2.1% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.25 | $25.41 | +0.6% | -7.2% | +5.9% | +2.1% | -2.8% | -2.1% |
| Nov 11 | Citigroup | Maintains | Buy → Buy | — | $18.60 | $18.51 | -0.5% | +4.2% | +4.2% | -2.6% | +5.1% | +0.0% |
| Aug 12 | Citigroup | Maintains | Buy → Buy | — | $17.39 | $17.56 | +1.0% | -2.5% | +6.3% | +3.3% | +4.9% | -1.5% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.39 | $17.56 | +1.0% | -2.5% | +6.3% | +3.3% | +4.9% | -1.5% |
| Jul 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.55 | $21.40 | -0.7% | +0.0% | +1.5% | -2.0% | -1.3% | -1.2% |
| Jun 24 | Guggenheim | Maintains | Buy → Buy | — | $22.80 | $24.03 | +5.4% | +1.4% | -1.3% | +0.0% | +0.4% | -5.0% |
| Jun 24 | Oppenheimer | Maintains | Outperform → Outperform | — | $22.80 | $24.03 | +5.4% | +1.4% | -1.3% | +0.0% | +0.4% | -5.0% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.10 | $19.28 | +0.9% | -1.8% | +2.6% | +0.6% | -0.1% | +7.8% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.81 | $21.91 | +0.5% | +0.3% | -0.6% | +3.5% | -0.1% | -3.1% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.31 | $25.90 | +2.3% | +5.2% | +2.3% | +0.2% | +3.4% | +2.0% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.08 | $28.46 | +1.4% | -3.1% | -0.6% | +1.4% | -0.0% | -3.0% |
| Sep 11 | Citigroup | Maintains | Buy → Buy | — | $27.29 | $27.57 | +1.0% | -7.1% | -6.2% | -0.1% | +3.3% | -2.4% |
| Sep 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.73 | $29.26 | +5.5% | -1.6% | -7.1% | -6.2% | -0.1% | +3.3% |
| Sep 10 | Oppenheimer | Maintains | Outperform → Outperform | — | $27.73 | $29.26 | +5.5% | -1.6% | -7.1% | -6.2% | -0.1% | +3.3% |
| Sep 10 | Goldman Sachs | Maintains | Buy → Buy | — | $27.73 | $29.26 | +5.5% | -1.6% | -7.1% | -6.2% | -0.1% | +3.3% |
| Aug 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.86 | $24.19 | +1.4% | +2.1% | -1.5% | +0.9% | -1.2% | -0.2% |
| Aug 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $23.95 | $24.06 | +0.5% | -0.4% | +2.1% | -1.5% | +0.9% | -1.2% |
| Jun 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.67 | $18.67 | +0.0% | -1.7% | +1.1% | +0.1% | +0.8% | -0.3% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.36 | $17.36 | +0.0% | +3.6% | -1.6% | +1.3% | +3.0% | +5.6% |
No insider trades available.
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
ArriVent's poster presentations at AACR 2026 provide preclinical validation for firmonertinib's mechanism, potentially strengthening confidence in its ongoing Phase 3 trial and supporting future regulatory approval odds.
Mar 17
8-K
ArriVent BioPharma, Inc. -- 8-K Filing
ArriVent BioPharma expects Phase 3 data for firmonertinib in EGFR exon 20 insertion NSCLC by mid-2026, with $312.8 million cash funding operations through Q3 2027.
Mar 5
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 3,016,132 | $70M | Reduced | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 1,528,893 | $35M | New | Mar 2026 |
| 3 | Vivo Capital, Llc | 885,916 | $20M | New | Mar 2026 |
| 4 | Point72 Asset Management | 748,195 | $17M | Added | Mar 2026 |
| 5 | Ubs Group Ag | 486,263 | $11M | Added | Mar 2026 |
| 6 | Millennium Management | 425,923 | $10M | Added | Mar 2026 |
| 7 | D.e. Shaw & Co | 368,795 | $9M | Added | Mar 2026 |
| 8 | Northern Trust Corp | 268,812 | $6M | Added | Mar 2026 |
| 9 | Vanguard Portfolio Management Llc | 253,852 | $6M | New | Mar 2026 |
| 10 | Nomura Holdings Inc | 242,050 | $6M | New | Mar 2026 |
| 11 | Morgan Stanley | 195,180 | $4M | Reduced | Dec 2025 |
| 12 | Citadel Advisors Llc | 166,157 | $4M | Reduced | Mar 2026 |
| 13 | Woodline Partners Lp | 147,639 | $3M | — | Mar 2026 |
| 14 | Adar1 Capital Management, Llc | 141,814 | $3M | New | Mar 2026 |
| 15 | Polymer Capital Management (Hk) Ltd | 122,276 | $3M | New | Mar 2026 |
| 16 | E Fund Management Co., Ltd. | 93,953 | $2M | New | Mar 2026 |
| 17 | Jane Street Group, Llc | 103,255 | $2M | New | Dec 2025 |
| 18 | Bank Of America Corp /de/ | 80,208 | $2M | Added | Mar 2026 |
| 19 | Bank Of New York Mellon Corp | 75,448 | $2M | Added | Mar 2026 |
| 20 | Qube Research & Technologies Ltd | 70,317 | $2M | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.52B
Enterprise Value
$908.0M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.07x
P/B
4.09x
P/S
—
P/FCF
-7.60x
EV/EBITDA
—
Shares Out
38.5M
Financials (TTM)
Revenue
$0
Net Income
-$145.2M
EBITDA
-$145.2M
Free Cash Flow
-$160.6M
Op Cash Flow
-$160.6M
EPS Basic
$-4.32
EPS Diluted
$-3.53
EPS Forward
$-3.76
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$333.2M
Total Liab.
$25.9M
Total Equity
$307.2M
Cash
$312.8M
LT Debt
$0
Book Value/Sh
$7.99
Debt/Equity
0.00x
Current Ratio
12.83
Quick Ratio
12.83
Returns & Growth
ROE
-54.1%
ROA
-49.9%
ROIC
-57.8%
Rev Growth YoY
+0.0%
EPS Growth YoY
-68.8%
Price Returns
2W
+6.5%
1M
-2.6%
3M
+31.8%
6M
+32.0%
12M
+42.4%
Technicals
52W High
$34.06
52W Low
$16.10
50d MA
$29.40
200d MA
$23.39
RSI (14)
57.40
ATR (14)
$1.74
Beta
0.86
Avg Volume
517K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$44.00
High
$45.00
Low
$43.00
Median
$44.00
Data updated apr 24, 2026 7:56pm
· Source: financialmodelingprep.com